Literature DB >> 17279547

Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.

A Osorio1, R L Milne, E Honrado, A Barroso, O Diez, R Salazar, M de la Hoya, A Vega, J Benítez.   

Abstract

Classification of rare missense variants in disease susceptibility genes as neutral or disease-causing is important for genetic counseling. Different criteria are used to help classify such variants in BRCA1 and BRCA2; however, the strongest evidence tends to come from segregation analysis and observed cooccurrence with known pathogenic mutations, which both require information that is not readily available in most circumstances. A likelihood-based model has been developed, integrating most of the data currently used to classify these variants. We have adapted the original model, including only that information that could be more easily obtained from a cancer genetics laboratory, such as loss of heterozygosity (LOH), grade, and immunohistochemical analysis to assess estrogen receptor (ER) status for the tumors of carriers of these variants. We also considered summary family history (personal or first-degree family history of bilateral breast or ovarian cancer), which was not incorporated into the original model. To test the ability of the modified model to classify missense variants in BRCA1, we analyzed 17 variants, of which 10 have previously been classified as pathogenic mutations or neutral polymorphisms. We also included a prior step consisting of the screening of the variants among 1,000 controls, with which we were able to classify five as neutral, based solely on their observed frequency. We found that combining this relatively easily collected information can be sufficient to classify variants as pathogenic or neutral if tumors from at least three carriers of the same variant can be collected and analyzed. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17279547     DOI: 10.1002/humu.20470

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  23 in total

Review 1.  Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.

Authors:  Amy M Dworkin; Tim H-M Huang; Amanda Ewart Toland
Journal:  Semin Cancer Biol       Date:  2009-02-20       Impact factor: 15.707

2.  LOH analysis should not be used as a tool to assess whether UVs of BRCA1/2 are pathogenic or not.

Authors:  E Beristain; I Guerra; N Vidaurrazaga; J Burgos-Bretones; M I Tejada
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

3.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.

Authors:  Noralane M Lindor; David E Goldgar; Sean V Tavtigian; Sharon E Plon; Fergus J Couch
Journal:  Oncologist       Date:  2013-04-24

Review 4.  The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.

Authors:  Ana Cristina Vargas; Leonard Da Silva; Sunil R Lakhani
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

5.  Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.

Authors:  William I Towler; Jie Zhang; Derek J R Ransburgh; Amanda E Toland; Chikashi Ishioka; Natsuko Chiba; Jeffrey D Parvin
Journal:  Hum Mutat       Date:  2012-12-12       Impact factor: 4.878

6.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

7.  A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.

Authors:  Leila Mohammadi; Maaike P Vreeswijk; Rogier Oldenburg; Ans van den Ouweland; Jan C Oosterwijk; Annemarie H van der Hout; Nicoline Hoogerbrugge; Marjolijn Ligtenberg; Margreet G Ausems; Rob B van der Luijt; Charlotte J Dommering; Johan J Gille; Senno Verhoef; Frans B Hogervorst; Theo A van Os; Encarna Gómez García; Marinus J Blok; Juul T Wijnen; Quinta Helmer; Peter Devilee; Christi J van Asperen; Hans C van Houwelingen
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

8.  Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.

Authors:  Arcangela De Nicolo; Emilio Parisini; Quan Zhong; Maurizia Dalla Palma; Kathryn A Stoeckert; Susan M Domchek; Katherine L Nathanson; Maria A Caligo; Marc Vidal; Michael E Cusick; Judy E Garber
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

9.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

Authors:  Douglas F Easton; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Richard J Wenstrup; Kristina Allen-Brady; Sean V Tavtigian; Alvaro N A Monteiro; Edwin S Iversen; Fergus J Couch; David E Goldgar
Journal:  Am J Hum Genet       Date:  2007-09-06       Impact factor: 11.025

10.  Methylation not a frequent "second hit" in tumors with germline BRCA mutations.

Authors:  Amy M Dworkin; Andrew D Spearman; Stephanie Y Tseng; Kevin Sweet; Amanda Ewart Toland
Journal:  Fam Cancer       Date:  2009-04-02       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.